Journal
PEDIATRIC RESEARCH
Volume 57, Issue 5, Pages 16R-20RPublisher
NATURE PUBLISHING GROUP
DOI: 10.1203/01.PDR.0000160447.83332.13
Keywords
-
Categories
Funding
- NHLBI NIH HHS [HL67841, HL61284, HL 60190] Funding Source: Medline
Ask authors/readers for more resources
Endothelin-1 (ET-1) is a 21-amino acid polypeptide produced primarily by vascular endothelial cells. First discovered in 1988 as a potent vasoconstrictor, it has subsequently been appreciated to participate in several biologic activities, including vascular smooth muscle proliferation, fibrosis, cardiac and vascular hypertrophy, and inflammation. Increasing data demonstrate alterations in ET-1 signaling in newborns, infants, and children with congenital heart defects that are associated with alterations in pulmonary blood flow. This review outlines the pathophysiologic role of the ET-1 cascade in the development of altered pulmonary vascular tone and reactivity that occurs with congenital heart disease and its repair, following the use of cardiopulmonary bypass. In addition, therapeutic implications for the use of novel ET receptor antagonists will be emphasized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available